MAIA Biotechnology initiated with an Outperform at Noble Capital

Noble Capital initiated coverage of MAIA Biotechnology with an Outperform rating and $14 price target. MAIA is in Phase 2 development with THIO, a drug directed at the telomeres of cancer cell chromosomes that the firm calls "a first-in-class cancer therapeutic with a dual mechanism of action." The lead THIO-101 trial is expected to announce data from the Phase 2 Part A safety cohort in non-small lung cancer, or NSCLC, in Q1, preliminary response data is expected in the second half and efficacy data is expected in late 2023 to early 2024, the firm noted.